Budesonide/formoterol maintenance and reliever therapy: An effective asthma treatment option?

European Respiratory Journal

Volumn 26, Issue 5, 2005, Pages 819-828

  Vogelmeier, Claus ^a   D'Urzo, A ^b   Pauwels, R ^c   Merino, J M ^d   Jaspal, M ^e   Boutet, S ^e   Naya, I ^g   Price, D ^f  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b Primary Care Lung Clinic   (Canada)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d HOSPITAL DONOSTIA   (Spain)

^e University of Aberdeen ^*

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Asthma; Budesonide formoterol; Salmeterol fluticasone; Seretide Advair ; Symbicort

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL; TERBUTALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; GENERAL CONDITION IMPROVEMENT; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SCHOOL CHILD; SIDE EFFECT;

EID: 27744557795     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00028305     Document Type: Article

References (35)

1. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
2. Pauwels RA, Lofdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
3. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
4. Zetterström O, Buhl R, Mellem H, et al. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 2001; 18: 262-268.
5. Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004; 64: 1597-1618.
6. Bateman ED, Frith L, Braunstein GL. Is overall asthma control being achieved? A hypothesis-generating study. Eur Respir J 2001; 17: 589-595.
7. Ind PW, Dal Negro R, Colman NC, Fletcher CP, Browning D, James MH. Addition of salmeterol to fluticasone propionate treatment in moderate to severe asthma. Respir Med 2003; 97: 555-562.
8. Balanag VM, Yunus F, Yang P-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents. Eur Respir J 2003; 22: Suppl. 45, 445s.
9. van der Woude HJ, Boorsma M, Bergqvist PBF, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004; 17: 89-95.
10. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
11. Busse WW, Chervinsky P, Condemi J, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol 1998; 101: 457-463.
12. Ganse E, Mörk A-C, Osman LM, et al. Factors affecting adherence to asthma treatment: patient and physician perspectives. Primary Care Respiratory Journal 2003; 12: 46-61.
13. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171: 129-136.
14. Barnes FJ. A single inhaler for asthma? Am J Respir Crit Care Med 2005; 171: 95-96.
15. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170: 836-844.
16. 2-agonist? Am J Respir Crit Care Med 2005; 171: 1060-1061.
17. American Thoracic Society (ATS). Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
18. Global Initiative for Asthma. Global strategy for asthma management and prevention. Publication No. 02-3659. Bethesda, MD, National Institutes of Health, 2002.
19. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardisation of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 16: 5-40.
20. 2-agonist use? Respir Med 2001; 95: 319-323.
21. Juniper EF, Buist S, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115: 1265-1279.
22. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47: 81-87.
23. Juniper EF, Stahl E, O'Byrne PM. Minimal important difference for the Asthma Control Questionnaire. Am J Respir Crit Care Med 2001; 163: Suppl. 2, A642.
24. Rabe KF, Pizzichini E, Ställberg B, et al. Single inhaler therapy with budesonide/formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed. J Allergy Clin Immunol 2004; 113: Suppl. 2, S116.
25. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20: 1403-1418.
26. Ind PW, Villasante C, Shiner RJ, et al. Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma. Eur Respir J 2002; 20: 859-866.
27. Pauwels RA, Sears MR, Campbell M, et al. Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003; 22: 787-794.
28. Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20: 225-240.
29. Global Initiative for Asthma. Pocket guide for asthma management and prevention. Publication No. 95-3659B. Bethesda, MD, National Institutes of Health, 1998.
30. National Asthma Education and Prevention Program. Guidelines for the diagnosis and management of asthma expert panel report 2. Publication No. 97-4051. Bethesda MD, National Institutes of Health, National Heart, Lung, and Blood Institute, 1997.
31. FitzGerald JM, Backer A, Sears MR, et al. Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 2004; 59: 550-556.
32. Masoli M, Weatherall M, Holt S, Beasley R. Clinical dose-response relationship of fluticasone propionate in adults with asthma. Thorax 2004; 59: 16-20.
33. Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust 2003; 178: 223-225.
34. Powell H, Gibson PG. Initial starting dose of inhaled corticosteroids in adults with asthma: a systemic review. Thorax 2004; 59: 1041-1045.
35. Reddel HK, Jenkins CR, Marks GB, et al. Optimal asthma control, starting with high doses of inhaled budesonide. Eur Respir J 2000; 16: 226-235.